Furthermore, some cancer patients with CTLA-4 treatment-related colitis showed high serum concentrations of IL-17, and a preclinical animal study further confirmed this finding and found that CTLA-4 blockade promoted Th17 T cell differentiation. This evidence concerns the gene CTLA4 and cancer.